GlassScriptPhysician profile
Ivan L Slavich
NPI 1669587960
$2,164.41
in general payments reported to CMS, 2019-2025
15 companies · $640 in 2025
The $640 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $100 · 2021: $400 · 2022: $378 · 2023: $14.39 · 2024: $395 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,049.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $505.24 | 2021-2022 | |
| Novo Nordisk INC | $321.03 | 2024-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $312.70 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $243.80 | 2024 | Inpefa |
| Amgen INC. | $177.30 | 2024-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.86 | 2020-2025 | Jardiance |
| Medtronic, INC. | $118.57 | 2025 | Symplicity G3 |
| E.R. Squibb & Sons, L.L.C. | $99.99 | 2022 | |
| Hikma Pharmaceuticals USA | $61.76 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $35.01 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $29.00 | 2021 | |
| Lilly USA, LLC | $28.37 | 2020 | |
| Edwards Lifesciences Corporation | $26.58 | 2024 | |
| Merck Sharp & Dohme LLC | $26.20 | 2021-2023 | Verquvo |
| Inogen, INC. | $18.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Slavich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.